1. Signaling Pathways
  2. PI3K/Akt/mTOR
  3. PI3K

PI3K

PI3K

Phosphoinositide 3-kinase

PI3K (Phosphoinositide 3-kinase), via phosphorylation of the inositol lipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), forms the second messenger molecule phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3) which recruits and activates pleckstrin homology domain containing proteins, leading to downstream signalling events crucial for proliferation, survival and migration. Class I PI3K enzymes consist of four distinct catalytic isoforms, PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ.

There are three major classes of PI3K enzymes, being class IA widely associated to cancer. Class IA PI3K are heterodimeric lipid kinases composed of a catalytic subunit (p110α, p110β, or p110δ; encoded by PIK3CA, PIK3CB, and PIK3CD genes, respectively) and a regulatory subunit (p85).

The PI3K pathway plays an important role in many biological processes, including cell cycle progression, cell growth, survival, actin rearrangement and migration, and intracellular vesicular transport.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-19312
    3-Methyladenine
    Inhibitor 99.91%
    3-Methyladenine (3-MA) is a PI3K inhibitor. 3-Methyladenine is a widely used inhibitor of autophagy via its inhibitory effect on class III PI3K.
    3-Methyladenine
  • HY-10108
    LY294002
    Inhibitor 99.95%
    LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively. LY294002 also inhibits CK2 with an IC50 of 98 nM. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM. LY294002 is an apoptosis activator.
    LY294002
  • HY-18085
    Quercetin
    Inhibitor 99.80%
    Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.
    Quercetin
  • HY-P0175
    740 Y-P
    Activator 99.96%
    740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone.
    740 Y-P
  • HY-15244
    Alpelisib
    Inhibitor 99.95%
    Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity.
    Alpelisib
  • HY-159852
    BBO-10203
    Ligand
    BBO-10203 (Compound 758) binds to the RBD region of PI3Kα, and inhibits the binding of K-, H-, and N-Ras to PI3Kα. BBO-10203 inhibits pAKT with an IC50 < 0.1 pM in BT474 cell.
    BBO-10203
  • HY-W004284R
    Heptadecanoic acid (Standard)
    Activator
    Heptadecanoic acid (Standard) is the analytical standard of Heptadecanoic acid. This product is intended for research and analytical applications. Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis[1].
    Heptadecanoic acid (Standard)
  • HY-10197
    Wortmannin
    Inhibitor 99.86%
    Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively.
    Wortmannin
  • HY-111783
    AZD-7648
    Inhibitor 99.86%
    AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity.
    AZD-7648
  • HY-N0728
    α-Linolenic acid
    Inhibitor 99.92%
    α-Linolenic acid, isolated from Perilla frutescens, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer.
    α-Linolenic acid
  • HY-13026
    Idelalisib
    Inhibitor 99.78%
    Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.
    Idelalisib
  • HY-101562
    Inavolisib
    Inhibitor 99.96%
    Inavolisib (GDC-0077) is a potent, orally active, and selective PI3Kα inhibitor (IC50=0.038 nM). Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib can be used for the study of breast cancer.
    Inavolisib
  • HY-50094
    Pictilisib
    Inhibitor 99.80%
    Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα with an IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
    Pictilisib
  • HY-70063
    Buparlisib
    Inhibitor 99.90%
    Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.
    Buparlisib
  • HY-50673
    Dactolisib
    Inhibitor 99.94%
    Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC50s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.
    Dactolisib
  • HY-12481
    SAR405
    Inhibitor 99.74%
    SAR405 is a first-in-class, selective, and ATP-competitive PI3K class III (PIK3C3) isoform Vps34 inhibitor (IC50=1.2 nM; Kd=1.5 nM). SAR405 inhibits autophagy induced either by starvation or by mTOR inhibition. Anticancer activity.
    SAR405
  • HY-17044
    Duvelisib
    Inhibitor 99.88%
    Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.
    Duvelisib
  • HY-15346
    Copanlisib
    Inhibitor 99.50%
    Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity.
    Copanlisib
  • HY-15097
    Myricetin
    98.42%
    Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.
    Myricetin
  • HY-100716
    Eganelisib
    Inhibitor 99.68%
    Eganelisib (IPI549) is a potent and selective PI3Kγ inhibitor with an IC50 of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases.
    Eganelisib
Cat. No. Product Name / Synonyms Application Reactivity

Phosphatidylinositol 3 kinases (PI3Ks) are a family of lipid kinases that integrate signals from growth factors, cytokines and other environmental cues, translating them into intracellular signals that regulate multiple signaling pathways. These pathways control many physiological functions and cellular processes, which include cell proliferation, growth, survival, motility and metabolism[1]

 

In the absence of activating signals, p85 interacts with p110 and inhibits p110 kinase activity. Following receptor tyrosine kinase (RTK) or G protein-coupled receptor (GPCR) activation, class I PI3Ks are recruited to the plasma membrane, where p85 inhibition of p110 is relieved and p110 phosphorylates PIP2 to generate PIP3. The activated insulin receptor recruits intracellular adaptor protein IRS1. Phosphorylation of IRS proteins on tyrosine residues by the insulin receptor initiates the recruitment and activation of PI3K. PIP3 acts as a second messenger which promotes the phosphorylation of Akt at Thr308 by PDK-1. RTK activation can also trigger Ras-Raf-MEK-ERK pathway. Activated Akt, ERK and RSK phosphorylate TSC2 at multiple sites to inhibit TSC1-TSC2-TBC1D7, which is the TSC complex that acts as a GTPase-activating protein (GAP) for the small GTPase RHEB. During inhibition of the TSC complex, GTP-loaded RHEB binds the mTOR catalytic domain to activate mTORC1. Glycogen synthase kinase 3β (GSK-3β) activates the TSC complex by phosphorylating TSC2 at Ser1379 and Ser1383. Phosphorylation of these two residues requires priming by AMPK-dependent phosphorylation of Ser1387. Wnt signaling inhibits GSK-3β and the TSC complex, and thus activates mTORC1. mTORC2 is activated by Wnt in a manner dependent on the small GTPase RAC1. Akt activation contributes to diverse cellular activities which include cell survival, growth, proliferation, angiogenesis, metabolism, and migration. Important downstream targets of Akt are GSK-3, FOXOs, BAD, AS160, eNOS, and mTOR. mTORC1 negatively regulates autophagy through multiple inputs, including inhibitory phosphorylation of ULK1, and promotes protein synthesis through activation of the translation initiation promoter S6K and through inhibition of the inhibitory mRNA cap binding 4E-BP1[1][2][3].

 

PI3Kδ is a heterodimeric enzyme, typically composed of a p85α regulatory subunit and a p110δ catalytic subunit. In T cells, the TCR, the costimulatory receptor ICOS and the IL-2R can activate PI3Kδ. In B cells, PI3Kδ is activated upon crosslinking of the B cell receptor (BCR). The BCR co-opts the co-receptor CD19 or the adaptor B cell associated protein (BCAP), both of which have YXXM motifs to which the p85α SH2 domains can bind. In lumphocytes, BTK and ITK contribute to the activation of PLCγ and promotes the generation of DAG and the influx of Ca2+, which in turn activate PKC and the CARMA1-, BCL 10- and MALT1 containing (CBM) complex. The resulting NF-κB inhibitor kinase (IKK) activation leads to the phosphorylation and the degradation of IκB, and to the nuclear accumulation of the p50-p65 NF-κB heterodimer. MyD88 is an adapter protein that mediates signal transduction for most TLRs and leads to activation of PI3K[4].

 

Reference:

[1]. Thorpe LM, et al. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.Nat Rev Cancer. 2015 Jan;15(1):7-24. 
[2]. Vanhaesebroeck B, et al. PI3K signalling: the path to discovery and understanding.Nat Rev Mol Cell Biol. 2012 Feb 23;13(3):195-203. 
[3]. Fruman DA, et al. The PI3K Pathway in Human Disease.Cell. 2017 Aug 10;170(4):605-635.
[4]. Lucas CL, et al. PI3Kδ and primary immunodeficiencies.Nat Rev Immunol. 2016 Nov;16(11):702-714. 

PI3Kα

PI3Kβ

PI3Kγ

PI3Kδ

PI3KC2α

PI3KC2β

PI3KC2γ

Vps34

PI3K

PI3KC3

p120γ

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

PI3K Inhibitors, Activators & Modulators
Product NamePI3KαPI3KβPI3KγPI3KδPI3KC2αPI3KC2βPI3KC2γVps34PI3KPI3KC3p120γPurity    
3-Methyladenine  
PtdIns3Kγ, IC50: 60 μM (Cell Assay)
    
Vps34, IC50: 25 μM (Cell Assay)
   99.91%
LY294002
p110α, IC50: 0.5 μM
p110β, IC50: 0.97 μM
 
p110δ, IC50: 0.57 μM
       99.95%
Quercetin 
PI3Kβ, IC50: 5.4 μM
PI3Kγ, IC50: 3 μM
PI3Kδ, IC50: 2.4 μM
       99.80%
740 Y-P        
PI3K
  99.96%
Alpelisib
p110α, IC50: 5 nM
p110α-H1047R, IC50: 4 nM
p110α-E545K, IC50: 4 nM
p110β, IC50: 1200 nM
p110γ, IC50: 250 nM
p110δ, IC50: 290 nM
       99.95%
Wortmannin        
PI3K, IC50: 3 nM
  99.86%
AZD-7648  
PI3Kγ, IC50: 1.37 μM
        99.86%
α-Linolenic acid        
PI3K
  99.92%
Idelalisib
p110α, IC50: 820 nM
p110β, IC50: 565 nM
p110γ, IC50: 89 nM
p110δ, IC50: 2.5 nM
   
hVps34, IC50: 978 nM
   99.78%
Inavolisib
PI3Kα, IC50: 0.038 nM
          99.96%
Pictilisib
p110α, IC50: 3 nM
p110α-H1047R, IC50: 3 nM
p110α-E545K, IC50: 3 nM
p110β, IC50: 33 nM
p110γ, IC50: 75 nM
p110δ, IC50: 3 nM
       99.80%
Buparlisib
p110α, IC50: 52 nM
p110α-H1047R, IC50: 58 nM
p110α-E545K, IC50: 99 nM
p110β, IC50: 166 nM
p110γ, IC50: 262 nM
p110δ, IC50: 116 nM
   
Vps34, IC50: 2.4 μM
   99.90%
Dactolisib
p110α, IC50: 4 nM
p110α-H1047R, IC50: 4.6 nM
p110α-E545K, IC50: 5.7 nM
p110β, IC50: 75 nM
p110γ, IC50: 5 nM
p110δ, IC50: 7 nM
       99.94%
SAR405       
Vps34, IC50: 1.2 nM
Vps34, Kd: 1.5 nM
   99.74%
Duvelisib
p110α, IC50: 1602 nM
p110β, IC50: 85 nM
p110γ, IC50: 27.4 nM
p110δ, IC50: 2.5 nM
       99.88%
Copanlisib
PI3Kα, IC50: 0.5 nM
PI3Kβ, IC50: 3.7 nM
PI3Kγ, IC50: 6.4 nM
PI3Kδ, IC50: 0.7 nM
       99.50%
Eganelisib
PI3Kα, IC50: 3.2 μM
PI3Kβ, IC50: 3.5 μM
PI3Kγ, IC50: 16 nM
        99.68%
Recilisib        
PI3K
  99.94%
Isorhamnetin        
PI3-K
  99.94%
PI-103
p110α, IC50: 8 nM
p110β, IC50: 88 nM
p110γ, IC50: 150 nM
p110δ, IC50: 48 nM
PI3KC2α, IC50: 1 μM
PI3KC2β, IC50: 26 nM
 
hsVPS34, IC50: 2.3 μM
   99.82%
YM-201636
p110α, IC50: 3.3 μM
          98.05%
Omipalisib
p110α, Ki: 0.019 nM
p110α-H1047R, Ki: 0.009 nM
p110α-E545K, Ki: 0.008 nM
p110α-E542K, Ki: 0.008 nM
p110β, Ki: 0.13 nM
p110γ, Ki: 0.06 nM
p110δ, Ki: 0.024 nM
       99.94%
Copanlisib dihydrochloride
PI3Kα, IC50: 0.5 nM
PI3Kβ, IC50: 3.7 nM
PI3Kγ, IC50: 6.4 nM
PI3Kδ, IC50: 0.7 nM
       99.55%
Taselisib
PI3Kα, Ki: 0.29 nM
PI3Kβ, Ki: 9.1 nM
PI3Kγ, Ki: 0.97 nM
PI3Kδ, Ki: 0.12 nM
       99.75%
Vps34-IN-1       
Vps34, IC50: 25 nM
   99.79%
hSMG-1 inhibitor 11j
PI3Kα, IC50: 92 nM
 
PI3Kγ, IC50: 60 nM
        99.82%
Fimepinostat
PI3Kα, IC50: 19 nM
PI3Kβ, IC50: 54 nM
PI3Kγ, IC50: 311 nM
PI3Kδ, IC50: 39 nM
       99.95%
PI3K/AKT-IN-1  
PI3Kγ, IC50: 6.99 μM
PI3Kδ, IC50: 4.01 μM
       99.64%
Esculetin        
PI3K
  ≥98.0%
Autophinib       
Vps34, IC50: 19 nM
   99.95%
Gedatolisib
PI3Kα, IC50: 0.4 nM
PI3Kα-H1047R, IC50: 0.6 nM
PI3Kα-E545K, IC50: 0.6 nM
PI3Kβ, IC50: 6 nM
PI3Kγ, IC50: 5.4 nM
PI3Kδ, IC50: 6 nM
       99.68%
Dihydrocapsaicin        
PI3K
  99.93%
Quercetin dihydrate 
PI3Kβ, IC50: 5.4 μM
PI3Kγ, IC50: 2.4 μM
PI3Kδ, IC50: 3.0 μM
       
Thymoquinone        
PI3K
  99.59%
GSK2636771 
PI3Kβ, Ki: 0.89 nM
PI3Kβ, IC50: 5.2 nM
         99.59%
PIK-90
p110α, IC50: 11 nM
p110β, IC50: 350 nM
p110γ, IC50: 18 nM
p110δ, IC50: 58 nM
PI3KC2α, IC50: 47 nM
PI3KC2β, IC50: 64 nM
 
hsVPS34, IC50: 830 nM
   99.70%
Umbralisib
PI3Kα, Kd: >10000 nM
PI3Kβ, Kd: >10000 nM
PI3Kγ, Kd: 1400 nM
PI3Kδ, EC50: 22.2 nM
PI3Kδ, Kd: 6.2 nM
       98.94%
PF-04691502
PI3Kα, Ki: 1.8 nM
PI3Kβ, Ki: 2.1 nM
PI3Kγ, Ki: 1.9 nM
PI3Kδ, Ki: 1.6 nM
       99.91%
Paxalisib
PI3Kα, Ki: 2 nM
PI3Kβ, Ki: 46 nM
PI3Kγ, Ki: 10 nM
PI3Kδ, Ki: 3 nM
       99.63%
ZSTK474
PI3Kα, IC50: 16 nM
PI3Kβ, IC50: 44 nM
PI3Kγ, IC50: 49 nM
PI3Kδ, IC50: 4.6 nM
       99.71%
AZD 6482
PI3Kα, IC50: 136 nM
PI3Kβ, IC50: 0.69 nM
PI3Kγ, IC50: 47.8 nM
PI3Kδ, IC50: 13.6 nM
 
PI3K-C2β, IC50: 54.1 nM
 
hVps34, IC50: 3390 nM
   99.93%
GO-203 TFA        
PI3K
  99.28%
hSMG-1 inhibitor 11e
PI3Kα, IC50: 61 nM
 
PI3Kγ, IC50: 92 nM
        99.81%
AS-252424
PI3Kα, IC50: 935 nM
PI3Kβ, IC50: 20 μM
PI3Kγ, IC50: 30 nM
PI3Kδ, IC50: 20 μM
       99.71%
Samotolisib
PI3Kα, IC50: 6.07 nM
PI3Kβ, IC50: 77.6 nM
PI3Kγ, IC50: 23.8 nM
PI3Kδ, IC50: 38 nM
       99.27%
Vps34-PIK-III
PI(3)Kα, IC50: 3.96 μM
 
PI(3)Kγ, IC50: 3.04 μM
PI(3)Kδ, IC50: 1.2 μM
   
Vps34, IC50: 18 nM
   99.63%
TGX-221 
p110β, IC50: 8.5 nM
 
p110δ, IC50: 211 nM
       99.74%
PIK-93
p110α, IC50: 39 nM
p110β, IC50: 590 nM
p110γ, IC50: 16 nM
p110δ, IC50: 120 nM
PI3KC2α, IC50: 16 μM
PI3KC2β, IC50: 140 nM
 
hsVPS34, IC50: 320 nM
   99.81%
Linperlisib   
PI3Kδ, IC50: 6.4 nM
       99.51%
AZD8186
PI3Kα, IC50: 35 nM
PI3Kβ, IC50: 4 nM
PI3Kγ, IC50: 675 nM
PI3Kδ, IC50: 12 nM
       99.97%
Apitolisib
PI3Kα, IC50: 5 nM
PI3Kβ, IC50: 27 nM
PI3Kγ, IC50: 14 nM
PI3Kδ, IC50: 7 nM
       99.29%
Bimiralisib
PI3Kα, IC50: 33 nM
PI3Kα-H1047R, IC50: 36 nM
PI3Kα-E545K, IC50: 136 nM
PI3Kα-E542K, IC50: 63 nM
PI3Kβ, IC50: 661 nM
PI3Kγ, IC50: 708 nM
PI3Kδ, IC50: 451 nM
   
Vps34, IC50: 6486 nM
   99.80%
TG100-115  
PI3Kγ, IC50: 83 nM
PI3Kδ, IC50: 235 nM
       99.41%
Leniolisib
PI3Kα, IC50: 280 nM
PI3Kβ, IC50: 480 nM
PI3Kγ, IC50: 2.57 μM
PI3Kδ, IC50: 11 nM
       99.28%
Parsaclisib   
PI3Kδ, IC50: 1 nM
       99.31%
Sophocarpine        
PI3K
  98.63%
Dactolisib Tosylate
p110α, IC50: 4 nM
p110α-H1047R, IC50: 4.6 nM
p110α-E545K, IC50: 5.7 nM
p110β, IC50: 75 nM
p110γ, IC50: 5 nM
p110δ, IC50: 7 nM
       99.87%
Voxtalisib
p110α, IC50: 39 nM
p110β, IC50: 113 nM
p110γ, IC50: 9 nM
p110δ, IC50: 43 nM
       99.02%
CNX-1351
PI3Kα, IC50: 6.8 nM
PI3Kβ, IC50: 166 nM
PI3Kγ, IC50: 3020 nM
PI3Kδ, IC50: 240.3 nM
       99.88%
IC-87114 
PI3Kβ, IC50: 75 μM
PI3Kγ, IC50: 29 μM
PI3Kδ, IC50: 0.5 μM
       99.83%
PI3K-IN-30
PI3Kα, IC50: 5.1 nM
PI3Kβ, IC50: 136 nM
PI3Kγ, IC50: 30.7 nM
PI3Kδ, IC50: 8.9 nM
       98.21%
BGT226
PI3Kα, IC50: 4 nM
PI3Kβ, IC50: 63 nM
PI3Kγ, IC50: 38 nM
        99.51%
PI3K-IN-1        
PI3K
  99.93%
PIK-75 hydrochloride
p110α, IC50: 5.8 nM
p110β, IC50: 1.3 μM
p110γ, IC50: 76 nM
p110δ, IC50: 510 nM
PI3KC2α, IC50: 10 μM
PI3KC2β, IC50: 1 μM
 
hsVPS34, IC50: 2.6 μM
   99.72%
Deoxyshikonin        
PI3K
  99.96%
GSK1059615
PI3Kα, IC50: 0.4 nM
PI3Kβ, IC50: 0.6 nM
PI3Kγ, IC50: 2 nM
PI3Kδ, IC50: 5 nM
       ≥99.0%
Pilaralisib
PI3Kα, IC50: 39 nM
PI3Kβ, IC50: 383 nM
PI3Kγ, IC50: 23 nM
PI3Kδ, IC50: 36 nM
   
Vps34, IC50: 6974 nM
   99.14%
1,3-Dicaffeoylquinic acid        
PI3K
  99.09%
KU-0060648
PI3Kα, IC50: 4 nM
PI3Kβ, IC50: 0.5 nM
PI3Kγ, IC50: 0.594 μM
PI3Kδ, IC50: 0.1 nM
       99.62%
Flupentixol dihydrochloride
PI3Kα, IC50: 127 nM
          99.73%
Serabelisib
p110α, IC50: 15 nM
p110β, IC50: 4500 nM
p110γ, IC50: 1900 nM
p110δ, IC50: 13900 nM
       99.44%
PKI-402
PI3Kα, IC50: 2 nM
PI3Kα-H1047R, IC50: 3 nM
PI3Kα-E545K, IC50: 3 nM
PI3Kβ, IC50: 7 nM
PI3Kγ, IC50: 16 nM
PI3Kδ, IC50: 14 nM
       98.43%
VS-5584
PI3Kα, IC50: 16 nM
PI3Kβ, IC50: 68 nM
PI3Kγ, IC50: 25 nM
PI3Kδ, IC50: 42 nM
   
Vps34, IC50: 7470 nM
   99.14%
AS-605240
PI3Kα, IC50: 60 nM
PI3Kβ, IC50: 270 nM
PI3Kγ, IC50: 8 nM
PI3Kγ, Ki: 7.8 nM
PI3Kδ, IC50: 300 nM
       98.51%
GNE-317        
PI3K
  99.14%
A66
p110α, IC50: 32 nM
p110α E545K, IC50: 30 nM
p110α H1047R, IC50: 43 nM
 
p110γ, IC50: 3480 nM
  
PI3K-C2β, IC50: 462 nM
     99.73%
SAR-260301
PI3Kα, IC50: 1539 nM
PI3Kβ, IC50: 23 nM
PI3Kγ, IC50: 10000 nM
PI3Kδ, IC50: 468 nM
  
PI3KC2γ, IC50: 3812 nM
Vps34, IC50: 183 nM
   99.95%
Buparlisib Hydrochloride
p110α, IC50: 52 nM
p110α-H1047R, IC50: 58 nM
p110α-E545K, IC50: 99 nM
p110β, IC50: 166 nM
p110γ, IC50: 262 nM
p110δ, IC50: 116 nM
   
Vps34, IC50: 2.4 μM
   99.88%
CGS 15943  
p110γ, IC50: 1.1 μM
p110δ, IC50: 8.47 μM
       99.96%
PI-103 Hydrochloride
p110α, IC50: 2 nM
p110β, IC50: 3 nM
p110γ, IC50: 15 nM
p110δ, IC50: 3 nM
       98.55%
Nemiralisib
PI3Kα, pIC50: 5.3
PI3Kβ, pIC50: 5.8
PI3Kγ, pIC50: 5.2
PI3Kδ, pKi: 9.9
       99.80%
PI3Kγ inhibitor AZ2
PI3Kα, pIC50: 5.1
PI3Kβ, pIC50: 4.5
PI3Kγ, pIC50: 9.3
PI3Kδ, pIC50: 6.6
       99.25%
AMG319
PI3Kα, IC50: 33 μM
PI3Kβ, IC50: 2.7 μM
PI3Kγ, IC50: 850 nM
PI3Kδ, IC50: 18 nM
       99.08%
Tenalisib  
PI3Kγ, IC50: 33 nM
PI3Kδ, IC50: 25 nM
       98.83%
PQR530
PI3Kα, Kd: 0.84 nM
PI3Kβ, Kd: 6.1 nM
PI3Kγ, Kd: 10 nM
PI3Kδ, Kd: 11 nM
 
PI3KC2β, Kd: 100 nM
     99.98%
Roginolisib
PI3Kα, IC50: 18500 nM
PI3Kβ, IC50: 2850 nM
 
PI3Kδ, IC50: 145 nM
       99.89%
MTX-531
PI3Kα, IC50: 6.4 nM
PI3Kβ, IC50: 233 nM
PI3Kγ, IC50: 8.3 nM
PI3Kδ, IC50: 1.1 nM
       99.87%
SF2523
PI3Kα, IC50: 34 nM
 
PI3Kγ, IC50: 158 nM
        98.25%
BGT226 maleate
PI3Kα, IC50: 4 nM
PI3Kβ, IC50: 63 nM
PI3Kγ, IC50: 38 nM
        99.92%
Ginkgolic Acid (C13:0)   
PI3Kδ, IC50: 2.49 μM
       99.92%
AZD3458
PI3Kα, pIC50: 5.1
PI3Kβ, pIC50: 4.5
PI3Kγ, pIC50: 9.1
PI3Kδ, pIC50: 6.5
PI3KC2α, pIC50: 5
PI3KC2β, pIC50: 7.5
PI3KC2γ, pIC50: 5.5
  
PI3KC3, pIC50: 5.1
 99.71%
Zandelisib   
PI3Kδ, IC50: 3.5 nM
       99.90%
BAY1082439
PI3Kα
PI3Kβ
 
PI3Kδ
       98.02%
Duvelisib (R enantiomer)        
PI3K
  99.00%
Pictilisib dimethanesulfonate
p110α, IC50: 3 nM
p110α-H1047R, IC50: 3 nM
p110α-E545K, IC50: 3 nM
p110β, IC50: 33 nM
p110γ, IC50: 75 nM
p110δ, IC50: 3 nM
       99.72%
Sonolisib
p110α, IC50: 0.1 nM
  
p110δ, IC50: 2.9 nM
      
p120γ, IC50: 1 nM
99.00%
4-Methylbenzylidene camphor        
PI3K
  99.87%
PI4KIIIbeta-IN-9
PI3Kα, IC50: 2 μM
 
PI3Kγ, IC50: 1046 nM
PI3Kδ, IC50: 152 nM
  
PI3KC2γ, IC50: 1 μM
    99.18%
Vps34-IN-2       
Vps34, IC50: 2 nM
   99.81%
GDC-0326
PI3Kα, Ki: 0.2 nM
PI3Kβ, Ki: 26.6 nM
PI3Kγ, Ki: 10.2 nM
PI3Kδ, Ki: 4 nM
       99.92%
PF-06843195
PI3Kα, IC50: 18 nM (in Rat1 fibroblasts)
PI3Kα, Ki: 0.018 nM
PI3Kβ, IC50: 360 nM (in Rat1 fibroblasts)
 
PI3Kδ, IC50: 160 nM (in Rat1 fibroblasts)
PI3Kδ, Ki: 0.28 nM
       98.01%
PF-04979064
PI3Kα, Ki: 0.13 nM
 
PI3Kγ, Ki: 0.111 nM
PI3Kδ, Ki: 0.122 nM
       99.54%
Sophocarpine monohydrate        
PI3K
  99.91%
alpha-Bisabolol        
PI3K
  
Brevianamide F
PI3Kα, IC50: 4.8 μM
          99.03%
Glaucocalyxin A        
PI3K
  99.39%
GNE-493
PI3Kα, IC50: 3.4 nM
PI3Kβ, IC50: 12 nM
PI3Kγ, IC50: 16 nM
PI3Kδ, IC50: 16 nM
       99.81%
PI-3065
p110α, IC50: 910 nM
p110β, IC50: 600 nM
 
p110δ, IC50: 5 nM
       98.97%
AS-604850
PI3Kα, IC50: 4.5 μM
 
PI3Kγ, IC50: 0.25 μM
PI3Kγ, Ki: 0.18 μM
        99.95%
PI3Kα-IN-9
PI3Kα, IC50: 4.4 nM
PI3Kβ, IC50: 153 nM
PI3Kγ, IC50: 128 nM
PI3Kδ, IC50: 146 nM
       99.17%
AMG 511
PI3Kα, Ki: 4 nM
PI3Kβ, Ki: 6 nM
PI3Kγ, Ki: 1 nM
PI3Kδ, Ki: 2 nM
       99.38%
YH-306        
PI3K
  98.34%
PI3K/mTOR Inhibitor-2
PI3Kα, IC50: 3.4 nM
PI3Kβ, IC50: 34 nM
PI3Kγ, IC50: 1 nM
PI3Kδ, IC50: 16 nM
       99.10%
Hederacolchiside A1        
PI3K
  ≥99.0%
PI3K-IN-31
PI3Kα, IC50: 3.7 nM
PI3Kβ, IC50: 74 nM
PI3Kγ, IC50: 14.6 nM
PI3Kδ, IC50: 9.9 nM
       99.55%
PIK-75
p110α, IC50: 5.8 nM
p110β, IC50: 1.3 μM
p110γ, IC50: 76 nM
p110δ, IC50: 510 nM
PI3KC2α, IC50: 10 μM
PI3KC2β, IC50: 1 μM
 
hsVPS34, IC50: 2.6 μM
   99.94%
PI4K-IN-1
PI3Kα, pIC50: 4.0
PI3Kβ, pIC50: <3.7
PI3Kγ, pIC50: 5.0
PI3Kδ, pIC50: <4.1
       98.61%
GSK-F1        
PI3KA, pIC50: 5.8
PI3KB, pIC50: 5.9
PI3KG, pIC50: 5.9
PI3KD, pIC50: 6.4
  
Leniolisib phosphate
PI3Kα, IC50: 280 nM
PI3Kβ, IC50: 480 nM
PI3Kγ, IC50: 2.57 nM
PI3Kδ, IC50: 11 nM
       99.10%
NSC781406
PI3Kα, IC50: 2 nM
PI3Kβ, IC50: 9.4 nM
PI3Kγ, IC50: 2.7 nM
PI3Kδ, IC50: 14 nM
       99.97%
IITZ-01  
PI3Kγ, IC50: 2.62 μM
        98.18%
AZD8154  
PI3Kγ
        99.88%
Izorlisib
PI3Kα, IC50: 14 nM
PI3Kα-H1047R, IC50: 5.6 nM
PI3Kα-E545K, IC50: 6.7 nM
PI3Kα-E542K, IC50: 6.7 nM
PI3Kβ, IC50: 120 nM
PI3Kγ, IC50: 36 nM
PI3Kδ, IC50: 500 nM
 
PI3KC2β, IC50: 5.3 μM
     99.01%
HS-173
PI3Kα, IC50: 0.8 nM
          99.04%
MTX-211        
PI3K
  99.81%
Seletalisib   
PI3Kδ, IC50: 12 nM
       99.79%
Acalisib
p110α, IC50: 5441 nM
p110β, IC50: 3377 nM
p110γ, IC50: 1389 nM
p110δ, IC50: 12.7 nM
   
hVps34, IC50: 12682 nM
   99.98%
AQX-016A        
PI3K
  98.00%
CZC24832 
PI3Kβ, IC50: 1.1 μM
PI3Kγ, IC50: 27 nM
PI3Kδ, IC50: 8.194 μM
       99.07%
Polygalasaponin F        
PI3K
  99.85%
PI3K/mTOR Inhibitor-4
PI3Kα, IC50: 0.63 nM
PI3Kβ, IC50: 94.54 nM
PI3Kγ, IC50: 22 nM
PI3Kδ, IC50: 9.2 nM
       
GNE-477
PI3Kα, IC50: 4 nM
          98.75%
AZD-8835
PI3Kα, IC50: 6.2 nM
PI3Kα-E545K, IC50: 6 nM
PI3Kα-H1047R, IC50: 5.8 nM
PI3Kβ, IC50: 431 nM
PI3Kγ, IC50: 90 nM
PI3Kδ, IC50: 5.7 nM
       98.62%
ETP-45658
PI3Kα, IC50: 22.0 nM
PI3Kβ, IC50: 129.0 nM
PI3Kγ, IC50: 717.3 nM
PI3Kδ, IC50: 39.8 nM
       98.97%
PKI-179
PI3Kα, IC50: 8 nM
PI3Kβ, IC50: 24 nM
PI3Kγ, IC50: 74 nM
PI3Kδ, IC50: 77 nM
       ≥98.0%
PI-828
p110α, IC50: 173 nM
          99.62%
PIK-294
p110α, IC50: 10 μM
p110β, IC50: 490 nM
p110γ, IC50: 160 nM
p110δ, IC50: 10 nM
       99.90%
Umbralisib hydrochloride
PI3Kα, Kd: >10000 nM
PI3Kβ, Kd: >10000 nM
PI3Kγ, Kd: 1400 nM
PI3Kδ, EC50: 22.2 nM
PI3Kδ, Kd: 6.2 nM
       99.04%
PI3K/mTOR Inhibitor-11
PI3Kα, IC50: 3.5 nM
  
PI3Kδ, IC50: 4.6 nM
       98.74%
SRX3207
PI3Kα, IC50: 861 nM
 
PI3Kγ, IC50: 11100 nM
PI3Kδ, IC50: 1280 nM
       98.50%
CAY10505  
PI3Kγ, IC50: 30 nM (Neurons)
        99.75%
NVP-BAG956
PI3Kα, IC50: 56 nM
PI3Kβ, IC50: 446 nM
PI3Kγ, IC50: 117 nM
PI3Kδ, IC50: 35 nM
       99.21%
TG 100713
PI3Kα, IC50: 165 nM
PI3Kβ, IC50: 215 nM
PI3Kγ, IC50: 50 nM
PI3Kδ, IC50: 24 nM
       99.49%
Ifupinostat
PI3Kα, IC50: 0.1 μM
          99.60%
KTC1101
PI3Kα, IC50: 3.72 nM
PI3Kβ, IC50: 36.29 nM
PI3Kγ, IC50: 17.09 nM
PI3Kδ, IC50: 1.22 nM
       98.09%
WYE-687
PI3K alpha, IC50: 81 nM
 
PI3K gamma, IC50: 3.11 μM
        98.05%
SB02024       
Vps34
   99.7%
FD223
PI3Kα, IC50: 51 nM
PI3Kβ, IC50: 29 nM
PI3Kγ, IC50: 37 nM
PI3Kδ, IC50: 1 nM
       98.05%
CHMFL-PI3KD-317
PI3Kα, IC50: 62.6 nM
PI3Kβ, IC50: 284 nM
PI3Kγ, IC50: 202.7 nM
PI3Kδ, IC50: 6 nM
 
PIK3C2B, IC50: 882.3 nM
 
Vps34, IC50: 1801.7 nM
   98.04%
PKI-179 hydrochloride
PI3Kα, IC50: 8 nM
PI3Kβ, IC50: 24 nM
PI3Kγ, IC50: 74 nM
PI3Kδ, IC50: 77 nM
       99.66%
GNE-490
PI3Kα, IC50: 3.5 nM
PI3Kβ, IC50: 25 nM
PI3Kγ, IC50: 15 nM
PI3Kδ, IC50: 5.2 nM
       
Pilaralisib analogue
PI3K-alpha
          99.74%
IPI-3063
p110α, IC50: 1170 nM
p110β, IC50: 1508 nM
p110γ, IC50: 2187 nM
p110δ, IC50: 2.5 nM
       99.22%
(S)-PI3Kα-IN-4
PI3Kα, IC50: 2.3 nM
          99.77%
Vulolisib
PI3Kα, IC50: 0.2 nM
PI3Kβ, IC50: 168 nM
PI3Kγ, IC50: 90 nM
PI3Kδ, IC50: 49 nM
       99.60%
GSK2292767   
PI3Kδ, pIC50: 10.1
       98.89%
AS-041164
PI3Kα, IC50: 240 nM
PI3Kβ, IC50: 1.4 μM
PI3Kγ, IC50: 70 nM
PI3Kδ, IC50: 1.7 μM
       99.02%
ETP-46321
p110α, Ki: 2.3 nM
PI3Kα-H1047R, Ki: 2.33 nM
PI3Kα-E545K, Ki: 1.77 nM
PI3Kα-E542K, Ki: 1.89 nM
p110β, Ki: 170 nM
p110γ, Ki: 179 nM
p110δ, Ki: 14.2 nM
       99.34%
ON 146040
PI3Kα, IC50: 14 nM
PI3Kβ, IC50: 3 μM
PI3Kγ, IC50: 1 μM
PI3Kδ, IC50: 20 nM
       
Parsaclisib hydrochloride   
PI3Kδ, IC50: 1 nM
       98.74%
LX2343        
PI3K, IC50: 15.99 μM
  99.80%
Roginolisib hemifumarate   
PI3Kδ, IC50: 145 nM
       99.80%
PI3K-IN-2
PI3Kα, IC50: 13 nM
PI3Kβ, IC50: 7.1 nM
PI3Kγ, IC50: 8.6 nM
PI3Kδ, IC50: 190 nM
       99.62%
PI3Kα-IN-4
PI3Kα, IC50: 1.8 nM
          99.76%
PARP/PI3K-IN-1
PI3Kα, pIC50: 8.25
PI3Kβ, pIC50: 6.54
PI3Kγ, pIC50: 6.08
PI3Kδ, pIC50: 8.13
       99.43%
PI3K-IN-37
PI3Kα, IC50: 6 nM
PI3Kβ, IC50: 8 nM
 
PI3Kδ, IC50: 4 nM
       ≥99.0%
PI3K-IN-22
PI3Kα, IC50: 0.9 nM
          99.50%
OMS14  
PI3Kγ
        99.09%
WYE-687 dihydrochloride
PI3K alpha, IC50: 81 nM
 
PI3K gamma, IC50: 3.11 μM
        ≥98.0%
NVS-PI3-4  
PI3Kγ
        99.40%
MJ04  
PI3Kγ, IC50: 3667 nM
        98.08%
TASP0415914  
PI3Kγ, IC50: 29 nM
        99.02%
PI3K-IN-18
PI3Kα, IC50: 41 nM
          ≥99.0%
GS-9901   
PI3Kδ, IC50: 1 nM
       99.97%
CHMFL-PI4K-127
PI3Kα, IC50: 191 ± 36 nM
PI3Kβ, IC50: 392 ± 27 nM
PI3Kγ, IC50: 324 ± 19 nM
PI3Kδ, IC50: 104 ± 3 nM
   
Vps34, IC50: 681 ± 25 nM
   99.94%
PF-4989216
PI3Kα, Ki: 0.6 nM
          99.38%
FD274
PI3Kα, IC50: 0.65 nM
PI3Kβ, IC50: 1.57 nM
PI3Kγ, IC50: 0.42 nM
PI3Kδ, IC50: 0.65 nM
       99.45%
α-Linolenic acid (Standard)        
PI3K
  
PIK-293
PI3Kα, IC50: 100 μM
PI3Kβ, IC50: 10 μM
PI3Kγ, IC50: 25 μM
PI3Kδ, IC50: 0.24 μM
       99.41%
CAL-130 Hydrochloride
p110α, IC50: 115 nM
p110β, IC50: 56 nM
p110γ, IC50: 6.1 nM
p110δ, IC50: 1.3 nM
       98.74%
NVP-QAV-572        
PI3K, IC50: 10 nM
  98.05%
PI3Kδ-IN-15
p110α, IC50: 152 nM
p110β, IC50: 145 nM
p110γ, IC50: 15.3 nM
p110δ, IC50: 0.5 nM
       99.52%
PI3Kα/mTOR-IN-1
PI3Kα, Ki: 12.5 nM
PI3Kα, IC50: 7 nM (Cell Assay)
          99.30%
Umbralisib tosylate
PI3Kα, Kd: >10000 nM
PI3Kβ, Kd: >10000 nM
PI3Kγ, Kd: 1400 nM
PI3Kδ, Kd: 6.2 nM
       
Nemiralisib hydrochloride
PI3Kα, pIC50: 5.3
PI3Kβ, pIC50: 5.8
PI3Kγ, pIC50: 5.2
PI3Kδ, pKi: 9.9
       
Umbralisib sulfate
PI3Kα, Kd: >10000
PI3Kβ, Kd: >10000
PI3Kγ, Kd: 1400
PI3Kδ, Kd: 6.2
       
PI3Kδ-IN-8
PI3Kα, IC50: 377.2 nM
PI3Kβ, IC50: 241.6 nM
PI3Kγ, IC50: 17.9 nM
PI3Kδ, IC50: 3.3 nM
       
LAS191954   
PI3Kδ, IC50: 2.6 nM
       
PI3K/HDAC-IN-1
PI3Kα, IC50: 42 nM
PI3Kβ, IC50: 101 nM
PI3Kγ, IC50: 67 nM
PI3Kδ, IC50: 8.1 nM
       
PI3K/mTOR Inhibitor-1
PI3Kα, IC50: 20 nM
PI3Kβ, IC50: 376 nM
PI3Kγ, IC50: 204 nM
PI3Kδ, IC50: 46 nM
       
CHF-6523   
PI3Kδ
       
IHMT-PI3Kδ-372   
PI3Kδ, IC50: 14 nM
       
PI3K-IN-6
PI3Kα, IC50: 850 nM
PI3Kβ, IC50: 7.8 nM
 
PI3Kδ, IC50: 5.3 nM
       
PI3Kγ inhibitor 2  
PI3Kγ, Ki: 4 nM
        
PI3Kdelta inhibitor 1   
PI3Kδ, IC50: 1.3 nM
       
PI3K-IN-9   
PI3Kδ
       
PI3Kγ inhibitor 4
PI3Kα, IC50: 300 nM
 
PI3Kγ, IC50: 40 nM
        
PI3Kα-IN-6
PI3Kα
          
PI3K/mTOR Inhibitor-9
PI3Kα, IC50: 6.6 μM
PI3Kβ, IC50: >10 μM
PI3Kγ, IC50: 6.6 μM
PI3Kδ, IC50: 0.8 μM
       
PI3K-IN-33
PI3Kα, IC50: 11.73 μM
PI3Kβ, IC50: 6.09 μM
 
PI3Kδ, IC50: 11.18 μM
       
PI3Kδ-IN-10   
PI3Kδ, IC50: 2 nM
       
PI3Kα-IN-25
PI3Kα
          
TRPM7-IN-1        
PI3K
  
D-106669
PI3Kα, IC50: 0.129 μM
          
SN32976
PI3Kα, IC50: 15.1 nM
PI3Kβ, IC50: 461 nM
PI3Kγ, IC50: 110 nM
PI3Kδ, IC50: 134 nM
       99.49%
PI3Kα-IN-19
p110α
          
ATM Inhibitor-3        
PI3K
  
PI3Kδ-IN-11   
PI3Kδ, IC50: 27.5 nM
       
PI3K-IN-38
p110α, IC50: 0.541 μM
          
PI3Kδ/BET-IN-1   
PI3Kδ, IC50: 112 nM
       
NVP-CLR457
PI3Kα, IC50: 12 ± 1.5 nM
PI3Kβ, IC50: 8.3 ± 1.0 nM
PI3Kγ, IC50: 230 ± 31 nM
PI3Kδ, IC50: 8.3 ± 2.0 nM
       
TGX-155 
PI3Kβ
         
PI3K-IN-34
PI3Kα, IC50: 8.43 μM
PI3Kβ, IC50: 15.84 μM
 
PI3Kδ, IC50: 30.62 μM
       
ATM Inhibitor-4        
PI3K
  
PD-1/PD-L1-IN-54        
PI3K
  
PI3K/HDAC-IN-2
PI3Kα, IC50: 226 nM
PI3Kβ, IC50: 279 nM
PI3Kγ, IC50: 467 nM
PI3Kδ, IC50: 29 nM
       
PI3K/mTOR Inhibitor-3        
PI3K
  
PI3Kα-IN-5
PI3Kα, IC50: 0.7 nM
          
SU-11752  
p110γ, IC50: 1.1 μM
        
PP30  
p110γ, IC50: 0.68 μM
p110δ, IC50: 0.99 μM
       
(R)-IHMT-PI3Kδ-372   
PI3Kδ, IC50: 19 nM
       99.75%
IHMT-PI3K-315  
PI3Kγ, IC50: 4.0 nM
PI3Kδ, IC50: 9.1 nM
       
PI3Kδ-IN-22
PI3Kα, pKi: 7.3
PI3Kβ, pKi: 7.7
PI3Kγ, pKi: 6.5
PI3Kδ, pKi: 9.3
       
PI3Kα-IN-13
PI3Kα
          
(Rac)-AZD8186
PI3Kα, IC50: 35 nM
PI3Kβ, IC50: 4 nM
PI3Kγ, IC50: 675
PI3Kδ, IC50: 12
       
PI3K/mTOR Inhibitor-12
PI3Kα, IC50: 0.06 nM
          
Umbralisib R-enantiomer   
PI3Kδ
       99.52%
PI3Kγ ligand 1  
PI3Kγ
        
COX-2/PI3K-IN-2        
PI3K, IC50: 2.78 nM
  
MEK/PI3K-IN-2
PI3Kα, IC50: 107 ± 21 nM
PI3Kβ, IC50: 3880 ± 725 nM
PI3Kγ, IC50: 2567 ± 364 nM
PI3Kδ, IC50: 137 ± 7 nM
       
ATR-IN-15        
PI3K, IC50: 5131 nM
  
PH14
PI3Kα, IC50: 20.3 nM
          99.29%
PI3Kδ/γ-IN-3  
PI3Kγ, IC50: 16 nM
PI3Kδ, IC50: 1 nM
       
PP487
p110α, IC50: 0.046 μM
p110β, IC50: 0.24 μM
p110γ, IC50: 0.1 μM
p110δ, IC50: 0.027 μM
       
PI3Kδ-IN-20   
PI3Kδ, IC50: 6.4 nM
       
PI3Kα-IN-7
PI3Kα
PI3Kβ
         
PI3K-IN-35
PI3Kα, IC50: 13.98 μM
PI3Kβ, IC50: 7.22 μM
 
PI3Kδ, IC50: 10.94 μM
       
PI3Kα-IN-11
PI3Kα
          
PI3Kγ inhibitor 7
PI3Kα, IC50: 4768 nM
PI3Kβ, IC50: 878.1 nM
PI3Kγ, IC50: 3.42 nM
PI3Kδ, IC50: 355.2 nM
       
17β-Hydroxywortmannin        
PI3K, IC50: 0.5 nM
  
MEK/PI3K-IN-1
PI3Kα, IC50: 130 ± 13 nM
PI3Kβ, IC50: 1537 ± 188 nM
PI3Kγ, IC50: 2745 ± 485 nM
PI3Kδ, IC50: 236 ± 29 nM
       
PI3K/mTOR Inhibitor-8
PI3Kα, IC50: 0.46 nM
          
XJTU-L453
PI3Kα
          
Flupentixol
PI3Kα, IC50: 127 nM
          
IHMT-PI3K-455
PI3Kα, IC50: 6.717 μM
PI3Kβ, IC50: 42.04 nM
PI3Kγ, IC50: 7.1 nM
PI3Kδ, IC50: 0.57 nM
       
Isorhamnetin (Standard)        
PI3-K
  
PI3Kδ-IN-12
PI3Kα, pKi: 6.7
PI3Kβ, pKi: 6.4
PI3Kγ, pKi: 6.5
PI3Kδ, pIC50: 5.8
PI3Kδ, pKi: 8.0
       
PI3Kδ-IN-21
PI3Kα, IC50: 7034 nM
PI3Kβ, IC50: 1660 nM
 
PI3Kδ, IC50: 13.6 nM
       
PI3K/mTOR Inhibitor-14        
PI3K, IC50: 171.4 nM
  
PI3Kδ-IN-18   
PI3Kδ, IC50: 0.1 nM
       
PI3Kα-IN-14
PI3Kα, IC50: 0.14 nM
PI3Kβ, IC50: 25.89 nM
PI3Kγ, IC50: 2.45 nM
PI3Kδ, IC50: 5.69 nM
       
CXJ-2        
PI3K
  
COX-2/PI3K-IN-1        
PI3K, IC50: 1.14 nM
  
PI3Kα-IN-20
PI3Kα
          
PI3Kδ/γ-IN-2  
PI3Kγ, IC50: 4.3 nM
PI3Kδ, IC50: 1 nM
       
PI3Kα-IN-23
PI3Kα-H1047R
          
PI3K/mTOR Inhibitor-17
PI3Kα, IC50: 0.45 nM
          
PI3K-IN-10        
PI3K
  
TYM-3-98   
PI3Kδ, IC50: 7.1 nM
       
PI3Kδ-IN-23   
PI3Kδ, IC50: 0.27 nM
       
PI3Kα-IN-8
PI3Kα, IC50: 0.012 μM
PI3Kβ, IC50: 0.21 μM
PI3Kγ, IC50: 0.18 μM
PI3Kδ, IC50: 0.11 μM
       
PI3Kα-IN-1
PI3Kα, IC50: <0.5 nM
          
PI3K/VEGFR2-IN-1        
PI3K, IC50: 2.21 μM
  
LTURM 36 
PI3Kβ, IC50: 5.0 μM
 
PI3Kδ, IC50: 0.64 μM
       
Topoisomerase I/II inhibitor 3        
PI3K
  
mTOR inhibitor-13
PI3Kα, IC50: 119 nM
          
PI3Kα-IN-24
PI3Kα, IC50: 0.025 μM
          
mTOR inhibitor-17
PI3Kα, IC50: 1359 nM
          
PI3K-IN-54
p110α, IC50: 0.22 nM
p110β, IC50: 1.4 nM
 
p110δ, IC50: 0.38 nM
       
MIPS-9922 
PI3Kβ, IC50: 63 nM
 
PI3Kδ, IC50: 2200 nM
       
(S)-GSK-F1
PI3Kα, pIC50: 5.6
PI3Kβ, pIC50: 5.1
 
PI3Kδ, pIC50: 5.6
       
PI3Kγ inhibitor 1
PI3Kα, IC50: 10 μM
PI3Kβ, IC50: 10 μM
PI3Kγ, IC50: 100 nM
PI3Kδ, IC50: 100 nM
       
AS2541019   
p110δ
       
mTOR inhibitor-16
PI3Kα, IC50: 82 nM
          
AM-0687
PI3Kα, IC50: 17600 nM
PI3Kβ, IC50: 2840 nM
PI3Kγ, IC50: 3530 nM
PI3Kδ, IC50: 2.9 nM
       
TGX-115 
PI3Kβ, IC50: 0.13 μM
 
PI3Kδ, IC50: 0.63 μM
       
CAL-130 Racemate   
PI3Kδ
       
PIK-C98
PI3Kα, IC50: 0.59 μM
PI3Kβ, IC50: 1.64 μM
PI3Kγ, IC50: 0.74 μM
PI3Kδ, IC50: 3.65 μM
       
mTOR inhibitor-10
PI3Kα, IC50: 825 nM
          
CAL-130
p110α, IC50: 115 nM
p110β, IC50: 56 nM
p110γ, IC50: 6.1 nM
p110δ, IC50: 1.3 nM
       
PI3kδ inhibitor 1   
PI3Kδ, IC50: 3.8 nM